

ASX:NRT

NASDAQ:NVGN

Novogen Ltd  
(Company)

ABN 37 063 259 754

---

#### Capital Structure

Ordinary Shares on  
issue:

250 M

---

#### Board of Directors

**Dr Graham Kelly**  
Chairman &  
Executive Director

**Steve Coffey**  
Non Executive Director

**John O'Connor**  
Non Executive Director

**Prof Peter Gunning**  
Non Executive Director

## ASX RELEASE

20 February 2015

# Interim Report

for the half-year ended December 31, 2014

**Sydney, February 20, 2015.** Attached are the Interim Report documents required to be lodged with the ASX under Listing Rule 4.2A. The following is an overview of matters detailed in the Interim Report.

#### Highlights of the 6-month period:

- **Cantrixil commences pathway to clinic with initiation of large-scale manufacturing process**
- **Pre-IND meeting held with FDA regarding Cantrixil and clearance received to proceed with pre-clinical program**
- **Confirmation of extension of potent in vitro anti-cancer activity of TRXE-009 against adult brain cancer stem cells (glioblastoma) to paediatric brain cancers – medulloblastoma and DIPG – as well as the common childhood cancer, neuroblastoma**
- **Discovery of potent in vitro activity of TRXE-009 against melanoma cells, leading the Company to believe that it has discovered the first drug with preferential activity against cancer cells with a common embryonic origin (neural crest and neural tube stem cells)**
- **Identification of lead anti-tropomyosin lead candidate, ATM3507 (Anisina)**
- **Private placements of stock to Australian private investors and US investment funds raising an aggregate of \$7.7M**

The Company is pleased to report that it has made considerable strides in consolidating its two drug technology platforms with the identification of three lead candidate anti-cancer drugs that can now proceed to the formal process of being made 'clinic-ready'.

The underlying rationale of this dual technology approach is to achieve a level of anti-cancer effect not previously realized. Cytotoxic chemotherapy remains the backbone of chemotherapy and appears likely to for the foreseeable future. It is, however, ineffective in preventing tumor recurrence. The Novogen strategy is a simple one – to develop two families of chemotherapy drugs that we intend finally to deliver long-term remission in the majority of patients across the full cancer spectrum.

The identification of Cantrixil, TRXE-009 and Anisina in this reporting period has been a critically important development in providing what the Company believes will be the means to executing that strategy.

## Capital Raisings

The Company conducted two capital-raising in the reporting period.

The first was conducted in Australia via the ASX Bookbuild facility in November 2014 and raising \$1,855,000 (excluding transaction costs).

The second was managed by US investment bank, HC Wainwright & Co, and placed \$5,862,600 (excluding transaction cost) worth of stock with 3 US investment funds.

## Financial Summary

The loss for the consolidated entity for the half-year to 31 December 2014 after providing for income tax and non-controlling interest amounted to \$2,247,407 compared to a loss of \$3,055,263 for the previous corresponding period.

The current assets for the consolidated entity as at 31 December 2014 were \$8,203,262 (June 2014: \$2,638,025) with current liabilities of \$2,244,760 (June 2014: \$3,247,063).

## About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT – based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our websites [www.novogen.com](http://www.novogen.com)

For more information please contact:

### Corporate Contact

Dr. Graham Kelly  
Executive Chairman & CEO  
Novogen Group  
[Graham.Kelly@novogen.com](mailto:Graham.Kelly@novogen.com)  
+61 (0) 2 9472 4100

### Media Enquiries

Cristyn Humphreys  
Chief Operating Officer  
Novogen Group  
[Cristyn.Humphreys@novogen.com](mailto:Cristyn.Humphreys@novogen.com)  
+61 (0) 2 9472 4111

### Forward Looking Statement

*This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "appear," "intends," "hopes," "anticipates," "believes," "could," "should," "would," "may," "target," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to the*

*ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to events that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to the Company's two proprietary technology platforms, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factors including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.*